Fusion Antibodies and Isca Diagnostics announce collaboration on antibodies.
Queens University Belfast spin-out Fusion Antibodies has announced plans to collaborate with Isca Diagnostics, commercialising technology from the University of Exeter, on developing antibodies. Specifically, the two life science firms will be working on the diagnosis and therapy of aspergillosis; a variety of diseases caused by fungal infection. Most humans inhale spores from the Aspergillus…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
